TNXP
Tonix Pharmaceuticals Holding Corp. NASDAQ Listed May 10, 2012$13.62
After hrs
$14.09
+0.00%
Mkt Cap $193.5M
52w Low $11.60
3.5% of range
52w High $69.97
50d MA $13.73
200d MA $21.28
P/E (TTM)
-0.9x
EV/EBITDA
0.6x
P/B
0.5x
Debt/Equity
0.0x
ROE
-50.6%
P/FCF
-1.3x
RSI (14)
—
ATR (14)
—
Beta
1.76
50d MA
$13.73
200d MA
$21.28
Avg Volume
400.1K
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
26 Main Street · Chatham, NJ 07928 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -3.16 | -3.98 | -25.9% | 13.41 | +1.9% | -1.3% | +1.1% | +11.6% | +5.8% | +17.6% | — |
| Nov 10, 2025 | AMC | -3.59 | -3.59 | +0.0% | 16.84 | +1.8% | +4.1% | +5.2% | -4.1% | -5.6% | -0.2% | — |
| Aug 11, 2025 | AMC | -3.10 | -3.86 | -24.5% | 44.97 | +1.5% | +32.9% | +36.9% | +32.5% | +14.2% | -10.9% | — |
| May 12, 2025 | AMC | -3.23 | -2.84 | +12.1% | 19.19 | +0.8% | +5.2% | +15.1% | +20.4% | +45.9% | +38.6% | — |
| Mar 18, 2025 | AMC | -6.23 | -9.77 | -56.8% | 20.53 | -5.4% | -19.8% | -11.4% | +12.2% | +48.6% | +45.0% | — |
| Nov 12, 2024 | AMC | -203.00 | -23.00 | +88.7% | 14.50 | +4.8% | -2.6% | -3.4% | -9.6% | -8.3% | +12.2% | — |
| Aug 16, 2024 | AMC | -991.00 | -1928.00 | -94.6% | 44.74 | +35.1% | -0.5% | -15.1% | -19.5% | -26.2% | -24.0% | — |
| Apr 1, 2024 | AMC | -4984.03 | -2747.60 | +44.9% | 607.68 | +0.1% | +0.4% | +4.5% | -1.6% | -8.7% | -2.3% | — |
| Mar 25, 2024 | AMC | -1.64 | -0.86 | +47.6% | 1049.60 | -0.2% | +2.1% | -0.3% | -43.3% | -42.1% | -41.9% | — |
| Nov 9, 2023 | AMC | -4760.38 | -5846.65 | -22.8% | 1504.00 | +0.0% | -0.2% | -1.1% | -2.1% | +0.2% | -0.3% | — |
| Aug 10, 2023 | AMC | -8881.79 | -8562.30 | +3.6% | 3135.04 | -2.0% | -1.3% | -5.0% | -2.2% | -4.8% | -5.4% | — |
| May 8, 2023 | AMC | -7987.22 | -10383.39 | -30.0% | 10178.02 | -0.2% | -30.9% | -39.6% | -43.7% | -39.3% | -39.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4 | TD Cowen | Initiates | Buy | $22 | $13.60 | $13.41 | -1.4% | -4.2% | -0.7% | +8.0% | +0.1% | — |
| Mar 20 | Noble Capital Markets | Maintains | Outperform → Outperform | — | $16.47 | $16.72 | +1.5% | +10.4% | +39.8% | +85.2% | +80.8% | +74.6% |
| Jul 22 | Alliance Global Partners | Maintains | Buy → Buy | — | $56.02 | $58.30 | +4.1% | +0.6% | +1.4% | -5.9% | +3.4% | -1.8% |
| Aug 1 | Alliance Global Partners | Maintains | Buy → Buy | — | $3424.00 | $3488.00 | +1.9% | -3.7% | -5.6% | -6.5% | -8.9% | -4.7% |
| Jun 2 | Alliance Global Partners | Maintains | Buy → Buy | — | $6016.00 | $6272.00 | +4.3% | +0.0% | +5.3% | +3.7% | +1.6% | +0.5% |
| Jan 12 | Alliance Global Partners | Maintains | Buy → Buy | — | $18800.00 | $18302.02 | -2.6% | +27.7% | +38.3% | +14.9% | +10.6% | +25.5% |
| Apr 18 | Noble Capital Markets | Maintains | Outperform → Outperform | — | $120256.00 | $123200.00 | +2.4% | -7.5% | -5.2% | -6.1% | -11.5% | -15.9% |
| Aug 31 | Alliance Global Partners | Maintains | Buy → Buy | — | $443584.00 | $444672.00 | +0.2% | +1.8% | +4.8% | +6.8% | +1.9% | +0.7% |
| Aug 11 | Alliance Global Partners | Maintains | Buy → Buy | — | $496640.00 | $486720.00 | -2.0% | -7.2% | -9.5% | -12.4% | -12.0% | -13.9% |
| Feb 25 | Alliance Global Partners | Maintains | Buy → Buy | — | $800000.00 | $858304.00 | +7.3% | -2.4% | -4.8% | -2.4% | -2.4% | -9.6% |
| Nov 18 | B. Riley FBR | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Nov 18 | Oppenheimer | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Nov 18 | Roth Capital | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Nov 18 | Cantor Fitzgerald | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Nov 18 | Roth Capital | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| Apr 18 | Roth Capital | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| Jul 27 | Roth Capital | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Jul 27 | B. Riley FBR | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Jun 6 | B. Riley FBR | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 18 | Roth Capital | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| Sep 7 | Cantor Fitzgerald | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Sep 7 | Roth Capital | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Jun 2 | Cantor Fitzgerald | Maintains | Speculative Buy → Buy | — | — | — | — | — | — | — | — | — |
| Feb 17 | Oppenheimer | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Feb 17 | Cantor Fitzgerald | Maintains | Buy → Speculative Buy | — | — | — | — | — | — | — | — | — |
| Feb 17 | Cantor Fitzgerald | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Nov 4 | Cantor Fitzgerald | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jun 12 | Oppenheimer | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| May 7 | Janney Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 6 | Janney Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Oct 1 | Roth Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
No insider trades available.
8-K · 8.01
!! High
Tonix Pharmaceuticals Holding Corp. -- 8-K 8.01: Material Event / Announcement
Tonix Pharmaceuticals secured Group Purchasing Organization coverage for TONMYA reaching approximately 35 million U.S. commercially insured individuals, significantly expanding patient access and revenue potential.
May 6
8-K · 8.01
!! High
Tonix Pharmaceuticals Holding Corp. -- 8-K 8.01: Material Event / Announcement
Tonix Pharmaceuticals' TNX-1700 candidate reversed aging-related gastric inflammation in preclinical studies, potentially positioning the fusion protein as a therapeutic for inflammatory aging disorders and supporting pipeline advancement.
Apr 23
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
TNXP's Phase 2 field study launch timeline for TNX-4800 positions the vaccine candidate for potential near-term clinical progress, which could drive stock momentum if enrollment meets expectations.
Mar 31
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
TNXP initiated a Phase 1 clinical trial, signaling progress in its pipeline; investors should monitor efficacy data as positive results could drive stock appreciation and validate the company's development strategy.
Mar 26
8-K · 4.01
!!! Very High
Unknown — 8-K 4.01: Auditor Change / Resignation
TNXP's auditor change raises red flags about potential accounting disagreements or control issues, which could indicate underlying financial problems that warrant immediate investor scrutiny.
Mar 18
8-K
Unknown — 8-K Filing
Tonix secured $207.6M cash to fund its Lyme disease vaccine development through 2027 trials, providing substantial runway for clinical advancement and reducing near-term financing risk, though success depends entirely on regulatory approval and trial outcomes.
Mar 13
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
TNXP's pain relief drug met its primary trial endpoint with statistical significance, validating its therapeutic efficacy and potentially clearing a major development hurdle toward commercialization.
Mar 10
8-K · 8.01
!! High
Tonix Pharmaceuticals Holding Corp. -- 8-K 8.01: Material Event / Announcement
Tonix Pharmaceuticals secured Nasdaq approval to upgrade its stock listing from the Capital Market to the Global Select Market on March 3, 2026, signaling improved financial standing and enhanced visibility.
Mar 3
8-K · 8.01
!! High
Tonix Pharmaceuticals Holding Corp. -- 8-K 8.01: Material Event / Announcement
Tonix Pharmaceuticals generated $1.4 million in TONMYA revenue post-launch, with management projecting adequate cash runway into Q1 2027.
Feb 3
Data updated apr 27, 2026 5:13am
· Source: massive.com